Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at day of consent;~* Is a male, or is a non-pregnant non-lactating female who is either of non-child-bearing potential, or is using adequate means of birth control;~* Has a h/o of urinary incontinence from neurogenic bladder of spinal cord injury etiology;~* Has impairment based on the American Spinal Injury Association (ASIA);~* Use clean intermittent catheterization;~* Has urinary incontinence between scheduled catheterization;~* Capable of understanding and complying with the protocol.~Exclusion Criteria:~* Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency;~* Have any medical condition that precludes their participation in the study, or may confound the outcome of the study;~* History of major lower urinary tract surgery, procedures;~* Has an active skin disorder, affecting TDS application site areas;~* Hypersensitivity to the investigational drug;~* Has participated in any study involving administration of an investigational compound within 30 days before this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxybutynin transdermal system (Type: EXPERIMENTAL): Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).